South Korea Health Ministry's New Pricing Policy Draws Ire From Local Generics Makers
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs' new pricing policy, currently being re-crafted, is drawing criticism from the country's domestic generic drug makers because part of the new policy is calling for much lower prices on generics and original products coming off patent protection
You may also be interested in...
South Korea Drug Pricing Strategies Needed Now, Says Merck KGaA's South Korean President Juergen Koenig
To ramp up pharmaceutical sales, the company may have to overcome some considerable challenges directly linked to the country's increasingly indebted health care system.
South Korea Drug Pricing Strategies Needed Now, Says Merck KGaA's South Korean President Juergen Koenig
To ramp up pharmaceutical sales, the company may have to overcome some considerable challenges directly linked to the country's increasingly indebted health care system.
South Korea Drug Pricing Strategies Needed Now, Says Merck KGaA's South Korean President Juergen Koenig
HONG KONG - South Korea needs to clarify drug pricing regulations and speed up its decision-making process for new products if it hopes to attract, or even maintain, investment in the R&D pharmaceutical space